Despite a positive initial prognosis, six months later Bridges was told the cancer had spread to his liver and he was given between one and two years to live.
His only option is chemosaturation, a highly intensive targeted therapy which is not offered on the NHS, but which is available privately at a cost of £40,000-£46,000 a session.
Although it will not save Bridges’ life, it could extend it.
Jo Gumbs, the chief executive of the charity Ocular Melanoma UK, said a recent study, external suggested the treatment could make a difference in nine out of 10 patients.
“Whether people have a complete response, a partial response, or stability, that’s classed as a good outcome, because uveal melanoma can be such an aggressive cancer.”
A spokesperson for the National Institute for Health and Care Excellence (NICE) said its guidance concluded that chemosaturation could be used, but there were some “uncertainties about its safety and efficacy” and its use was recommended with sufficient oversight.